REDX Pharma ROCK2 inhibitors in chronic kidney disease

Hardman & Co Report Report DownloadsREDX Pharma (LON:REDX)  new management team is continuing to focus its financial resources on progressing lead candidates in oncology and fibrotic disease into the clinic. An extensive internal review, led by the new CEO Lisa Anson has reinforced the vision of a streamlined pipeline in these two disease areas, with the aim of progressing drug candidates to deliver clinical proof-of-concept. 2019 is expected to be a busy year for REDX, with several major milestones due. Meanwhile, REDX has disclosed, for the first time, the profiles of its ROCK2 inhibitors in in vitro and an in vivo kidney damage model, showing potential best-in-class results.

Strategy: REDX is focused on the discovery and early clinical development of small molecule therapeutics in oncology and fibrotic disease. It is also focused on taking assets through proof-of-concept clinical trials and then partnering them for late-stage development and commercialisation.

Poster presentation: REDX’s poster at the American Society of Nephrology in San Diego, presents, for the first time, the profile of its ROCK2 inhibitors. In vitro and in vivo data show selective modulation of markers of fibrosis pathways through ROCK2 inhibition, with no cardiovascular safety concerns.

ROCK2 programme: REDX is primarily investigating the effect of ROCK2 inhibition in fibrotic diseases (including IPF), with CKD an area of secondary interest. The ROCK2 programme is expected to enter preclinical development in 2H’19 in non-alcoholic steatohepatitis (NASH), and then the clinic in 2H’20.

Risks: After a difficult period, REDX has emerged in much better shape. While all early-stage pharma/biotech companies carry substantial risks and are capital- intensive, the rewards can be substantial, as evidenced by the successful disposal of the company’s BTK programme for $40m in cash in 2017.

Investment summary: The strengthened management team is moving forward with a revised business plan that focuses cash resources on progressing its drug leads in oncology and fibrotic disease to proof-of-concept early clinical development. Big pharma has been shown to pay handsome prices for novel and/or de-risked assets with clinical data, reinforcing REDX’s strategy. This can generate good returns and shareholder value for companies such as REDX Pharma.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Hardman & Co

    More articles like this

    Hardman & Co

    Redx Pharma Phase I trial resumed

    REDX is a clinical-stage R&D company focused on drugs targeting oncology and fibrotic disease. 2018 was a year that reset the benchmarks – new management team, restructured organisation focused on two therapeutic areas, and a clean

    Hardman & Co

    REDX Pharma RXC006: first anti-fibrosis development candidate

    REDX Pharma (LON:REDX) is a clinical-stage biotechnology company focused on drugs targeting oncology and fibrotic diseases. An extensive review, led by the new CEO, has reinforced the vision of a streamlined pipeline in these two disease

    Hardman & Co

    Redx Pharma Streamlined, focused and good value

    Redx Pharma (LON:REDX) is a clinical-stage R&D company focused on drugs targeting oncology and fibrotic disease. 2018 was a year that reset the benchmarks – new management team, restructured organisation focused on two therapeutic areas, and

    Hardman & Co

    Redx Pharma Back to the clinic

    Redx Pharma Plc (LON:REDX) new management team is continuing to focus its financial resources on progressing its lead candidates in oncology and fibrotic disease into the clinic. When the first patient was treated with RXC004, its

    Hardman & Co

    Redx Pharma Clinical and corporate update

    The new management team of Redx Pharma Plc (LON:REDX) is focusing its financial resources (ca.£10m) on progressing its lead candidates in oncology and fibrotic disease into the clinic. Although the first patient was treated recently in

    Hardman & Co

    Redx Pharma Streamlined and clean

    Redx Pharma Plc (LON:REDX) has emerged from administration with a refocused R&D pipeline and in a very clean financial state with £13.6m net cash in the bank. The group’s strategy has been validated by the successful

    Hardman & Co

    Redx Pharma Plc CARB-X – new strategic collaboration

    Although Redx Pharma Plc (LON:REDX) has only been operational since late-2010, it has already discovered several valuable drug candidates, the first of which is about to begin clinical trials. Although management is focusing resources on the

    Hardman & Co

    Redx Pharma Plc RXC005 BTK inhibitor – watch this space

    Although Redx Pharma Plc (LON:REDX) has only been in operation since late-2010, it has already created several valuable drug candidates that are about to begin clinical development. Progress into the clinic will enhance significantly the value

    Hardman & Co

    Redx Pharma Plc Porcupine inhibitor enhances anti-PD-1 effect

    Although Redx Pharma Plc (LON:REDX) has only been in operation since late-2010, it has already created several valuable drug candidates that are about to begin clinical development. Progress into the clinic will enhance significantly the value

    Hardman & Co

    Redx Pharma Plc Advancing to clinic, increasing value

    Although Redx Pharma Plc (LON:REDX) has only been in operation since late-2010, it has already created several valuable drug candidates that are about to begin clinical development. Progress into the clinic will enhance significantly the value